Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176665 · ClinicalTrials.gov registry record · Phase 1
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
A Phase 1 study of Neoplasms and Neoplasm Metastasis, sponsored by Shanghai EpimAb Biotherapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 14
- Study locations
NCT05176665: Recruiting Phase 1 study of Neoplasms and Neoplasm Metastasis, sponsored by Shanghai EpimAb Biotherapeutics Co..
NCT05176665 is a Phase 1 study of Neoplasms and Neoplasm Metastasis that is actively recruiting participants, run by Shanghai EpimAb Biotherapeutics Co.. The registered enrollment target is 152 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 14 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05176665, a Phase 1 study of Neoplasms and Neoplasm Metastasis, is actively recruiting participants, sponsored by Shanghai EpimAb Biotherapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Conditions Studied
Interventions
- DRUG EMB-01
Study Locations (14)
Other
- Hunan Cancer Hospital - Changsha
- West China Hospital, Sichuan University - Chengdu
- The Sixth Affiliated Hospital of Sun Yat-Sen University - Guangzhou
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Hangzhou
- Harbin Medical University Cancer Hospital - Harbin
- Shandong Cancer Hospital - Jinan
- Gansu Provincial Hospital - Lanzhou
- The Affiliated hospital of Qingdao University - Qingdao
- Fudan University Shanghai Cancer Center - Shanghai
- The First Affiliated Hospital of Xi'an Jiaotong University - Xi'an
- First Affiliated Hospital of Zhengzhou University - Zhengzhou
Texas
- MD Anderson Cancer Center - Houston
Beijing Municipality
- Beijing cancer Hospital - Beijing
Guangdong
- Nanfang Hospital - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT05176665 shows while recruiting
NCT05176665 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which EMB-01 is the first listed.
NCT05176665 lists 14 locations in 4 states (Other, Texas, Beijing Municipality).
Frequently Asked Questions
What is clinical trial NCT05176665 about?
NCT05176665 is a clinical study titled "EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers". This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
What is the current status of trial NCT05176665?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2021-10-21. Estimated completion is 2025-12-31.
What conditions does trial NCT05176665 study?
This clinical trial studies the following conditions: Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor.
What interventions are being tested in trial NCT05176665?
The interventions under investigation include: EMB-01 (DRUG).
Who is sponsoring clinical trial NCT05176665?
This trial is sponsored by Shanghai EpimAb Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05176665 being conducted?
This trial has 14 study locations across Texas, Beijing Municipality, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05176665's enrollment target sits among peer trials
152 55th of 158 higher than 103 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI